Akebia Therapeutics, Inc. (NASDAQ:AKBA – Get Rating) COO Michel Dahan sold 20,412 shares of the stock in a transaction on Wednesday, March 1st. The shares were sold at an average price of $0.88, for a total value of $17,962.56. Following the completion of the transaction, the chief operating officer now directly owns 269,515 shares in the company, valued at approximately $237,173.20. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Akebia Therapeutics Stock Up 4.0 %
AKBA opened at $0.97 on Monday. The company has a fifty day simple moving average of $0.75 and a 200 day simple moving average of $0.47. Akebia Therapeutics, Inc. has a 12 month low of $0.24 and a 12 month high of $2.93. The stock has a market cap of $177.80 million, a P/E ratio of -1.10 and a beta of 0.84.
Analyst Upgrades and Downgrades
A number of research analysts have recently weighed in on AKBA shares. StockNews.com downgraded Akebia Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, March 1st. HC Wainwright reissued a “neutral” rating and issued a $1.25 price target on shares of Akebia Therapeutics in a research note on Wednesday, February 22nd. Seven analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, Akebia Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $1.75.
Institutional Inflows and Outflows
Akebia Therapeutics Company Profile
Akebia Therapeutics, Inc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat.
- Get a free copy of the StockNews.com research report on Akebia Therapeutics (AKBA)
- MarketBeat Week in Review – 2/27 – 3/3
- The 3 Most Upgraded Stocks Are Reversing
- How to Find Blue Chip Dividend Stocks
- Zscaler, Inc Plummets, Is It Time To Buy The Dip?
- What is a Good Dividend Yield? How to Decide
Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.